Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059462 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT00059462 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 56 participants.
The verdict
NCT00059462, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
Interventions
- DRUG HAART
- DRUG Interleukin-2 SA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059462
The ClinicalTrials.gov registry entry for NCT00059462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HAART is the first listed.
NCT00059462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00059462 about?
NCT00059462 is a clinical study titled "Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection". The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
What is the current status of trial NCT00059462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2002-12. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00059462?
The interventions under investigation include: HAART (DRUG), Interleukin-2 SA (DRUG).
Who is sponsoring clinical trial NCT00059462?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.